If you or someone you know has received a prostate cancer diagnosis, here's where to start, what to ask and how to plan ...

Prostate and colorectal cancers are two of the most common cancers affecting men in the U.S., and Black men face ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

"I'm so lucky to have people in my life who didn't hightail it out," actor and three-time cancer survivor Colin Egglesfield tells PEOPLE.

An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved ...

Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Researchers investigated how Mindfulness-Based Cancer Recovery and Tai Chi/Qijong interventions could reduce distress levels in cancer survivors.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

I’ve been part of a pilot study for a cancer survivors’ group called Create to Heal, meeting at the regional cancer hospital in Santa Fe. We recently ...

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...